ROCKWELL MEDICAL, INC. Form 8-K February 15, 2019

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 11, 2019

ROCKWELL MEDICAL, INC.

(Exact name of registrant as specified in its charter)

Michigan (State or other jurisdiction of incorporation) 000-23661 (Commission File Number) **38-3317208** (IRS Employer Identification No.)

30142 Wixom Road, Wixom, Michigan 48393

(Address of principal executive offices, including zip code)


Edgar Filing: ROCKWELL MEDICAL, INC. - Form 8-K

(248) 960-9009

(Registrant s telephone number, including area code)

Not Applicable

(Former name or former address, if chan	ged since last report)



Edgar Filing: ROCKWELL MEDICAL, INC. - Form 8-K

<u>Item 2.02</u> <u>Results of Operations and Financial Condition.</u>

On February 11, 2019, Rockwell Medical, Inc. (the Company) presented at the 2019 BIO CEO & Investor Conference in New York City. A copy of the transcript from the presentation (the Transcript) is attached hereto as Exhibit 99.1 and is incorporated herein by reference. Additionally, the Company estimates that sales for the year ended December 31, 2018 will be in the range of \$62 million to \$63.5 million.

The information contained in this Item 2.02, including the related information set forth in the Transcript attached hereto and incorporated by reference herein, is being furnished and shall not be deemed filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise. The information in this Item 2.02 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or into any filing or other document pursuant to the Exchange Act, except as otherwise expressly stated in any such filing. Additionally, readers are cautioned that estimated result of operations for the period ended December 31, 2018 are unaudited and preliminary.

<u>Item 9.01</u> <u>Financial Statements and Exhibits.</u>

(d) *Exhibits*. The following exhibit is being furnished herewith:

EXHIBIT INDEX

Exhibit No.	Description
99.1	Transcript of Rockwell Medical, Inc. presentation at the 2019 BIO CEO & Investor Conference, dated February 11, 2019.

2

Edgar Filing: ROCKWELL MEDICAL, INC. - Form 8-K

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ROCKWELL MEDICAL, INC.

Date: February 15, 2019 /s/ Stuart Paul By: Stuart Paul

Chief Executive Officer